DE69636107T2 - Verfahren zur Reinigung von (S)-4-((dimethylamino)ethyl)-1H-Indol-5yl)-methyl)-2-Oxazolidinone - Google Patents
Verfahren zur Reinigung von (S)-4-((dimethylamino)ethyl)-1H-Indol-5yl)-methyl)-2-Oxazolidinone Download PDFInfo
- Publication number
- DE69636107T2 DE69636107T2 DE69636107T DE69636107T DE69636107T2 DE 69636107 T2 DE69636107 T2 DE 69636107T2 DE 69636107 T DE69636107 T DE 69636107T DE 69636107 T DE69636107 T DE 69636107T DE 69636107 T2 DE69636107 T2 DE 69636107T2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- ethyl acetate
- compound
- ethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 26
- 238000000746 purification Methods 0.000 title claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title description 4
- -1 (dimethylamino) ethyl Chemical group 0.000 title description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 113
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 2
- FBQSTBVWOKFVAG-UHFFFAOYSA-N 3-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1CCOC1=O FBQSTBVWOKFVAG-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 34
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 238000005580 one pot reaction Methods 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- RKJYNLQSYQZGHQ-LBPRGKRZSA-N (2s)-2-(butoxycarbonylamino)-3-(4-nitrophenyl)propanoic acid Chemical compound CCCCOC(=O)N[C@H](C(O)=O)CC1=CC=C([N+]([O-])=O)C=C1 RKJYNLQSYQZGHQ-LBPRGKRZSA-N 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YVTIPOBQALBPRK-LBPRGKRZSA-N (2S)-3-(4-aminophenyl)-2-(butoxycarbonylamino)propanoic acid Chemical compound CCCCOC(=O)N[C@H](C(O)=O)CC1=CC=C(N)C=C1 YVTIPOBQALBPRK-LBPRGKRZSA-N 0.000 description 4
- WNAVSKJKDPLWBD-VIFPVBQESA-N (4s)-4-[(4-aminophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(N)=CC=C1C[C@@H]1NC(=O)OC1 WNAVSKJKDPLWBD-VIFPVBQESA-N 0.000 description 4
- 229910004298 SiO 2 Inorganic materials 0.000 description 4
- OSUKKPIXRGNCBB-ZDUSSCGKSA-N butyl n-[(2s)-1-(4-aminophenyl)-3-hydroxypropan-2-yl]carbamate Chemical compound CCCCOC(=O)N[C@H](CO)CC1=CC=C(N)C=C1 OSUKKPIXRGNCBB-ZDUSSCGKSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- BTHMRXRBXYHLRA-FVGYRXGTSA-N methyl (2s)-2-amino-3-(4-nitrophenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 BTHMRXRBXYHLRA-FVGYRXGTSA-N 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 3
- QKXMWBLNSPNBEY-UHFFFAOYSA-N 4,4-diethoxy-n,n-dimethylbutan-1-amine Chemical compound CCOC(OCC)CCCN(C)C QKXMWBLNSPNBEY-UHFFFAOYSA-N 0.000 description 3
- 238000006641 Fischer synthesis reaction Methods 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 150000001989 diazonium salts Chemical class 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000006561 Cluster Headache Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- IMAZLPMRHTYSQZ-WWPIYYJJSA-N hydrazine (4S)-4-[(4-hydrazinylphenyl)methyl]-1,3-oxazolidin-2-one hydrochloride Chemical compound Cl.NN.C1=CC(NN)=CC=C1C[C@@H]1NC(=O)OC1 IMAZLPMRHTYSQZ-WWPIYYJJSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- GMTRSZXBNADBMK-VIFPVBQESA-N (2s)-2-amino-3-(4-aminophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=C(N)C=C1 GMTRSZXBNADBMK-VIFPVBQESA-N 0.000 description 1
- XNPWOQZTJFYSEI-QRPNPIFTSA-N (2s)-2-amino-3-(4-nitrophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 XNPWOQZTJFYSEI-QRPNPIFTSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical group C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- 0 *CCC1=C*c2ccc(C[C@@](CO3)*C3=O)cc12 Chemical compound *CCC1=C*c2ccc(C[C@@](CO3)*C3=O)cc12 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- IZGYIFFQBZWOLJ-CKAACLRMSA-N phaseic acid Chemical compound C1C(=O)C[C@@]2(C)OC[C@]1(C)[C@@]2(O)C=CC(/C)=C\C(O)=O IZGYIFFQBZWOLJ-CKAACLRMSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9516145 | 1995-08-07 | ||
| GBGB9516145.1A GB9516145D0 (en) | 1995-08-07 | 1995-08-07 | Improved chemical synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69636107D1 DE69636107D1 (de) | 2006-06-08 |
| DE69636107T2 true DE69636107T2 (de) | 2007-05-03 |
Family
ID=10778867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69636107T Expired - Lifetime DE69636107T2 (de) | 1995-08-07 | 1996-08-02 | Verfahren zur Reinigung von (S)-4-((dimethylamino)ethyl)-1H-Indol-5yl)-methyl)-2-Oxazolidinone |
| DE69624825T Expired - Lifetime DE69624825T2 (de) | 1995-08-07 | 1996-08-02 | Eintopfverfahren zur herstellung von 2-oxazolidinonderivate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69624825T Expired - Lifetime DE69624825T2 (de) | 1995-08-07 | 1996-08-02 | Eintopfverfahren zur herstellung von 2-oxazolidinonderivate |
Country Status (34)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5851400A (en) * | 1999-07-09 | 2001-01-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of aniline derivatives |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| ES2204302B2 (es) | 2002-08-07 | 2005-03-01 | Laboratorios Vita, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo. |
| EP1711493A2 (en) * | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
| EP1812428A2 (en) * | 2004-11-19 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Zolmitriptan crystal forms |
| WO2007023948A1 (ja) | 2005-08-25 | 2007-03-01 | Ube Industries, Ltd. | 光学活性（Ｓ又はＲ）－α－アミノ酸及び光学活性（Ｒ又はＳ）－α－アミノ酸エステルの製造方法 |
| WO2007083320A2 (en) | 2006-01-19 | 2007-07-26 | Matrix Laboratories Ltd | Conversion of aromatic diazonium salt to aryl hydrazine |
| WO2008007390A2 (en) * | 2006-07-10 | 2008-01-17 | Natco Pharma Limited | An improved process for purification of zolmitriptan |
| WO2008018090A2 (en) * | 2006-08-09 | 2008-02-14 | Matrix Laboratories Ltd | An improved process for the preparation of zolmitriptan |
| CZ2007158A3 (cs) * | 2007-02-26 | 2008-10-22 | Zentiva, A. S. | Zpusob prípravy zolmitriptanu |
| CZ301538B6 (cs) * | 2007-02-26 | 2010-04-07 | Zentiva, A. S. | Zpusob prípravy zolmitriptanu |
| CN101883766A (zh) * | 2007-10-03 | 2010-11-10 | 基因里克斯(英国)有限公司 | 制备佐米曲普坦、其盐和溶剂化物的方法 |
| CN101230047B (zh) * | 2008-02-04 | 2010-08-04 | 江苏中威药业有限公司 | 一种4-取代手性噁唑烷酮类化合物的制备方法 |
| US8906949B2 (en) | 2010-05-21 | 2014-12-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablets of zolmitriptan and process for preparing the same |
| CN101948443B (zh) * | 2010-08-17 | 2012-08-22 | 河南师范大学 | 一种简单、高效合成4-取代噁唑烷酮衍生物的方法 |
| WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
| US9006453B2 (en) | 2011-09-02 | 2015-04-14 | Emcure Pharmaceuticals Limited | Process for preparation of zolmitriptan |
| CN102964270B (zh) * | 2012-11-21 | 2015-01-07 | 合肥星宇化学有限责任公司 | 一种亚硫酸钠还原重氮盐合成肼的方法 |
| CN103275075B (zh) * | 2013-06-24 | 2015-01-07 | 成都天台山制药有限公司 | 佐米曲普坦及其制备方法 |
| WO2016037072A2 (en) * | 2014-09-04 | 2016-03-10 | Brown University | Enopeptin analogas and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879410A (en) * | 1971-02-08 | 1975-04-22 | Messrs Lab Guidotti & C S P A | 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity |
| GB1478108A (en) * | 1975-10-30 | 1977-06-29 | Nippon Chemipar Co Ltd | 5-benzyl-2-oxazolidone derivatives and a process for producing the same |
| GB8724912D0 (en) * | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
| CZ288351B6 (en) * | 1990-06-07 | 2001-05-16 | Astrazeneca Ab | Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof |
| GB9012672D0 (en) * | 1990-06-07 | 1990-08-01 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9401436D0 (en) * | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9423682D0 (en) * | 1994-11-23 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
| US6025374A (en) * | 1994-12-06 | 2000-02-15 | Merck Sharp & Dohme, Ltd. | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
-
1995
- 1995-08-07 GB GBGB9516145.1A patent/GB9516145D0/en active Pending
-
1996
- 1996-02-08 UA UA98031096A patent/UA53625C2/uk unknown
- 1996-08-02 AT AT96926465T patent/ATE227723T1/de active
- 1996-08-02 JP JP50822697A patent/JP3729503B2/ja not_active Expired - Lifetime
- 1996-08-02 RO ROA200400914A patent/RO121816B1/ro unknown
- 1996-08-02 PT PT02008427T patent/PT1227095E/pt unknown
- 1996-08-02 PT PT96926465T patent/PT843672E/pt unknown
- 1996-08-02 SI SI9630738T patent/SI1227095T1/sl unknown
- 1996-08-02 CN CNB01112010XA patent/CN1142904C/zh not_active Expired - Lifetime
- 1996-08-02 MX MX9801044A patent/MX9801044A/es unknown
- 1996-08-02 DE DE69636107T patent/DE69636107T2/de not_active Expired - Lifetime
- 1996-08-02 EP EP02008427A patent/EP1227095B1/en not_active Expired - Lifetime
- 1996-08-02 IL IL156733A patent/IL156733A/en not_active IP Right Cessation
- 1996-08-02 ES ES96926465T patent/ES2185790T3/es not_active Expired - Lifetime
- 1996-08-02 CZ CZ1998352A patent/CZ293050B6/cs not_active IP Right Cessation
- 1996-08-02 IL IL148030A patent/IL148030A/en not_active IP Right Cessation
- 1996-08-02 CZ CZ20031498A patent/CZ301603B6/cs not_active IP Right Cessation
- 1996-08-02 DK DK02008427T patent/DK1227095T3/da active
- 1996-08-02 CN CNB011330929A patent/CN1244579C/zh not_active Expired - Lifetime
- 1996-08-02 EP EP96926465A patent/EP0843672B1/en not_active Expired - Lifetime
- 1996-08-02 SK SK154-98A patent/SK285052B6/sk not_active IP Right Cessation
- 1996-08-02 CA CA2572508A patent/CA2572508C/en not_active Expired - Lifetime
- 1996-08-02 KR KR1019980700833A patent/KR100670704B1/ko not_active Expired - Lifetime
- 1996-08-02 AU AU66634/96A patent/AU718413B2/en not_active Expired
- 1996-08-02 IL IL12317196A patent/IL123171A/xx not_active IP Right Cessation
- 1996-08-02 HU HU9900188A patent/HU229966B1/hu unknown
- 1996-08-02 ES ES02008427T patent/ES2261545T3/es not_active Expired - Lifetime
- 1996-08-02 BR BR9609830A patent/BR9609830A/pt not_active Application Discontinuation
- 1996-08-02 DE DE69624825T patent/DE69624825T2/de not_active Expired - Lifetime
- 1996-08-02 PL PL96324881A patent/PL188805B1/pl unknown
- 1996-08-02 NZ NZ315040A patent/NZ315040A/xx not_active IP Right Cessation
- 1996-08-02 TR TR1998/00182T patent/TR199800182T1/xx unknown
- 1996-08-02 RO RO98-00214A patent/RO119618B1/ro unknown
- 1996-08-02 RU RU98104085/04A patent/RU2167875C2/ru active
- 1996-08-02 SI SI9630560T patent/SI0843672T1/xx unknown
- 1996-08-02 DK DK96926465T patent/DK0843672T3/da active
- 1996-08-02 AT AT02008427T patent/ATE325121T1/de active
- 1996-08-02 CA CA002227039A patent/CA2227039C/en not_active Expired - Lifetime
- 1996-08-02 WO PCT/GB1996/001885 patent/WO1997006162A1/en not_active Ceased
- 1996-08-02 CN CN96197237A patent/CN1092657C/zh not_active Expired - Lifetime
- 1996-08-02 US US09/011,045 patent/US6084103A/en not_active Expired - Lifetime
- 1996-08-06 MY MYPI96003220A patent/MY117571A/en unknown
- 1996-08-06 IN IN1742DE1996 patent/IN185148B/en unknown
- 1996-08-07 ZA ZA9606711A patent/ZA966711B/xx unknown
- 1996-08-07 AR ARP960103909A patent/AR006515A1/es active IP Right Grant
- 1996-10-01 TW TW085111923A patent/TW358811B/zh not_active IP Right Cessation
-
1998
- 1998-02-06 NO NO19980522A patent/NO311690B1/no not_active IP Right Cessation
- 1998-08-19 HK HK02108548.8A patent/HK1047094B/en not_active IP Right Cessation
-
2000
- 2000-02-02 US US09/496,409 patent/US6160123A/en not_active Expired - Lifetime
- 2000-04-25 IN IN454DE2000 patent/IN189756B/en unknown
- 2000-10-16 NO NO20005187A patent/NO311691B1/no not_active IP Right Cessation
-
2001
- 2001-07-27 JP JP2001228781A patent/JP2002037786A/ja not_active Withdrawn
- 2001-07-27 JP JP2001228782A patent/JP3739678B2/ja not_active Expired - Lifetime
-
2002
- 2002-02-06 IL IL14803002A patent/IL148030A0/xx unknown
- 2002-03-26 JP JP2002086955A patent/JP2002308858A/ja not_active Withdrawn
-
2003
- 2003-05-02 AR ARP030101543A patent/AR046236A2/es active IP Right Grant
-
2005
- 2005-11-18 JP JP2005334990A patent/JP4634286B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-31 JP JP2006152810A patent/JP2006225406A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69624825T2 (de) | Eintopfverfahren zur herstellung von 2-oxazolidinonderivate | |
| DE60120197T2 (de) | Verfahren zur herstellung von 2-amino-6-(alkyl)amino-4,5,6,7-tetrahydrobenzothiazolen | |
| DE69229339T2 (de) | Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung | |
| DE20216779U1 (de) | Diastereomer angereicherte Niederschläge oder Lösungen eines Sulfonatsalzes von Tamsulosin, erhältlich durch ein Verfahren zur optischen Auftrennung von Tamsulosin und Verbindungen und Zusammensetzungen, die damit verbunden sind | |
| DE69131657T2 (de) | Verfahren zur industriellen Herstellung von 4-Chloro-3-sulfamoyl-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)-Benzamid | |
| DE69622862T2 (de) | Verfahren zur herstellung von zyklischen verbindungen | |
| CH639953A5 (en) | Process for the preparation of novel indolyloxymethyl-2-oxazolidinone derivatives and use thereof for the preparation of 1-amino-3-(indolyloxy)-2-propanol derivatives | |
| DE69814395T2 (de) | Verfahren zur herstellung von alkoxyfuranon-amin-derivaten, durch dieses verfahren erhaltene verbindungen und verwendung dieser verbindungen | |
| DE1620326A1 (de) | Verfahren zur Herstellung von Aziridinderivaten | |
| DE69839056T2 (de) | Stereoisomere indolderivate, verfahren zu ihrer herstellung und ihre verwendung | |
| EP0271099A2 (de) | Substituierte Aminopropionsäureamide, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung sowie die bei der Herstellung anfallenden neuen Zwischenprodukte | |
| DE69616801T2 (de) | Eintopfverfahren zur herstellung von 2-oxazolidinonderivate | |
| DE60032453T2 (de) | Ein verfahren zur synthese von ritonavir | |
| DE60026161T2 (de) | Amidin-derivate, ihre herstellung und verwendung als medikamente | |
| DE69012407T2 (de) | Imidazobenzodiazepine und ihre Salze, Verfahren zur Herstellung, Verwendung als Arzneimittel und diese Substanzen enthaltende Zusammensetzungen. | |
| EP0672647B1 (de) | Verfahren zur Herstellung von Aminoethylglycin | |
| DE2362687A1 (de) | Verfahren zur razematspaltung von d,l-penicillamin | |
| DE69514115T2 (de) | Verfahren zur herstellung von levobupivacain und analogue aus l-lysin | |
| DE3023433A1 (de) | Acylaminobenzoesaeurederivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| DE2438077A1 (de) | Verfahren zur herstellung von propanolaminderivaten und nach dem verfahren hergestellte propanolaminderivate | |
| CH407147A (fr) | Procédé de préparation de composés antitumoraux | |
| DE2745280A1 (de) | Tricyclische verbindungen | |
| DE2619165A1 (de) | Indazolderivate und verfahren zu ihrer herstellung | |
| DE69333903T2 (de) | Optisch aktive 1-Phenylpyrrolidonderivate | |
| EP0512952A1 (de) | Octahydrobenzo(g)chinolin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |